FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

 0 17 11 -0	0_00::::=07	
	Washington,	D.C. 205

ANNUAL	STATEMENT	OF CH	IANGES IN	BENEFICIAL

OMB APPI	ROVAL
OMB Number:	3235-0362
Estimated average t	burden
hours per response:	1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

OWNERSHIP Form 3 Holdings Reported.

X Form 4 Transact	tions Reported.	Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	•				
1. Name and Address of Reporting Person* Young Caroline (Last) (First) (Middle) 2525 WEST END AVENUE			Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [CPIX] Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2020	Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify below)				
(Street) NASHVILLE (City)	TN (State)	37203 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Fil Form filed by One Re Form filed by More th Person	porting Person		

(City) (State)	(Zip)								
1. Title of Security (Instr. 3)	Table I - Non-Deriv	2A. Deemed	3.	4. Securities A	cquired (A	Beneficia	5. Amount of	6.	7. Nature of
	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)	Of (D) (Instr. 3	, 4 and 5)		Securities Beneficially Owned at end of	Ownership Form: Direct (D) or	Indirect Beneficial Ownership
				Amount	(A) or (D)	Price	Issuer's Fiscal Year (Instr. 3 and 4)	Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock	04/13/2020		L4	15(1)(2)	A	\$4.03	8,283	D	
Common Stock	04/14/2020		L4	15	A	\$4.01	8,298	D	
Common Stock	04/15/2020		L4	15	A	\$4.07	8,313	D	
Common Stock	04/16/2020		L4	15	A	\$4.02	8,328	D	
Common Stock	04/17/2020		L4	15	A	\$4.05	8,343	D	
Common Stock	04/20/2020		L4	15	A	\$4.03	8,358	D	
Common Stock	04/21/2020		L4	15	A	\$4.03	8,373	D	
Common Stock	04/22/2020		L4	15	A	\$4.03	8,388	D	
Common Stock	04/23/2020		L4	15	A	\$4.02	8,403	D	
Common Stock	04/24/2020		L4	15	A	\$4.02	8,418	D	
Common Stock	04/27/2020		L4	15	A	\$4.03	8,433	D	
Common Stock	04/28/2020		L4	15	A	\$4.02	8,448	D	
Common Stock	04/29/2020		L4	15	A	\$4.01	8,463	D	
Common Stock	04/30/2020		L4	15	A	\$4.01	8,478	D	
Common Stock	05/01/2020		L4	15	A	\$4.01	8,493	D	
Common Stock	05/04/2020		L4	15	A	\$3.98	8,508	D	
Common Stock	05/05/2020		L4	15	A	\$4.01	8,523	D	
Common Stock	05/06/2020		L4	15	A	\$3.97	8,538	D	
Common Stock	05/07/2020		L4	15	A	\$3.97	8,553	D	
Common Stock	05/08/2020		L4	15	A	\$4.04	8,568	D	
Common Stock	05/11/2020		L4	15	A	\$3.99	8,583	D	
Common Stock	05/12/2020		L4	15	A	\$3.99	8,598	D	
Common Stock	05/13/2020		L4	15	A	\$3.88	8,613	D	
Common Stock	05/14/2020		L4	15	A	\$3.81	8,628	D	
Common Stock	05/15/2020		L4	15	A	\$3.76	8,643	D	
Common Stock	05/18/2020		L4	15	A	\$3.82	8,658	D	
Common Stock	05/19/2020		L4	15	A	\$3.78	8,673	D	
Common Stock	05/20/2020		L4	15	A	\$3.77	8,688	D	
Common Stock	05/21/2020		L4	15	A	\$3.68	8,703	D	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Ad Of (D) (Instr. 3,		A) or Disposed	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Amount	(A) or (D)	Price				
Common Stock	05/22/2020		L4	15	A	\$3.61	8,718	D		
	Table II - Deriva	tive Securities	•		,	,	Owned	<u> </u>	<u> </u>	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

			(e.g., pt	its, cans, v	warra	ants,	options,	convertib	ne se	curities	5)			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	of Deriv	r osed) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/\)	ate	Amou Secu Unde Deriv	rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

- 1. The purchase reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.
- 2. Filing 2 of 6

Remarks:

Caroline Young by /s/ Michael 02/05/2021 Bonner as attorney-in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.